Lund, Sverige, 18:00 CET, 29 March 2019 – During the month of March, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to directed issue and repurchase of 505,000 series C shares, which were resolved upon by the board of directors on 1 March 2019 pursuant to the authorizations granted by the annual general meeting on 22 May 2018.
As of 29 March 2019, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 52,300,917 shares, of which 51,795,917 are ordinary shares with one vote per share and 505,000 are series C shares with one-tenth of a vote per share. The number of votes in the company amounts to 51,846,417 votes.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORTTM and CERAMENT® are registered trademarks.
For more information contact:
BONESUPPORT HOLDING AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46(0) 46 286 53 70
The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on 29 March 2019.